Depression News and Research

Latest Depression News and Research

Current economic crisis threatens to affect cancer incidence: Report

Although overall mortality from cancer is decreasing in the European Union, its incidence increased by almost 20%, from 2.1 million new cases in 2002 to 2.5 million in 2008, says a special issue of the European Journal of Cancer on cancer prevention, published today.

13 Sep 2010

Accord reached on draft declaration for MDG summit

World powers have reached an accord, after weeks of tough talks, on a document to be adopted at a Millennium Development summit this month for which [U.N.] Secretary General Ban Ki-moon is seeking billions of dollars of new funding,Agence France-Presse reports in an article that describes how representatives from donor and developing nations debated how best to pay for a kick start to the ambitious development goals first set at the Millennium summit in 2000.

13 Sep 2010

NAADAC and Hazelden partner to improve treatment for co-occurring disorders

NAADAC, the Association for Addiction Professionals, and Hazelden, the national nonprofit focused on addiction treatment, prevention and recovery announced today a new strategic partnership focused on improving the treatment of co-occurring disorders. The partnership announcement was made by NAADAC Executive Director Cynthia Moreno Tuohy during the National Conference on Addiction Disorders in Washington, D.C.

10 Sep 2010

Researchers present study results of psychosocial trauma experienced at 2006 Dawson College shooting

A research team from the McGill University Health Centre (MUHC) and Fernand-Seguin Research Centre of Louis-H. Lafontaine Hospital presented today the results of its three-year study, a world first, into the 2006 Dawson College shooting to the Government of Quebec's Ministry of Public Security.

10 Sep 2010

Purdue Pharma to present Butrans Transdermal System CIII clinical program data at PAINWeek 2010

Purdue Pharma L.P. will present data from the clinical program for Butrans™ (buprenorphine) Transdermal System CIII in a series of posters at PAINWeek®2010, September 8-10 in Las Vegas.

10 Sep 2010

Diplomat Specialty Pharmacy ranked #554 on Inc.'s Top 5000 list of fastest-growing private companies

Diplomat Specialty Pharmacy announced today they have earned a position of 554 on Inc. Magazine's exclusive, annual ranking of the fastest-growing private companies in America.

10 Sep 2010

Highlights of 23rd Congress of European College of Neuropsychopharmacology 2010

More than 7,000 psychiatrists, neurologists, psychologists and neuroscience researchers from all over the world met at the 23rd Congress of the European College of Neuropsychopharmacology (ECNP) from 28 August to 1 September 2010 in Amsterdam.

10 Sep 2010

New research examines how music could benefit treatment of depression, management of physical pain

New research into how music conveys emotion could benefit the treatment of depression and the management of physical pain. Using an innovative combination of music psychology and leading-edge audio engineering the project is looking in more detail than ever before at how music conveys emotion.

10 Sep 2010

Nation's four leading ADHD organizations seek to end persistent myths about ADHD

Four national organizations – ADHD Coaches Organization; Attention Deficit Disorder Association; ADDitude magazine; and Children and Adults with Attention-Deficit/Hyperactivity Disorder – are issuing a joint call to the public to assist children, adults, and families who are affected by ADHD.

9 Sep 2010

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder.

9 Sep 2010

Researchers to study suicide prevention program in high schools

With students returning to classes, University of Rochester Medical Center researchers are beginning a large, long-term study of the effectiveness of a unique suicide prevention program in high schools across New York and North Dakota.

8 Sep 2010

ECNP honors Kaj Blennow with 2010 Neuropsychopharmacology Award

The European College of Neuropsychopharmacology (ECNP) is pleased to announce Kaj Blennow as the recipient of the 2010 ECNP Neuropsychopharmacology Award in recognition of his original and influential contributions to Alzheimer's disease research. The ECNP Neuropsychopharmacology Award is presented annually and recognises distinguished research in neuropsychopharmacology and closely related disciplines. The award is accompanied by a prize of - 20,000.

8 Sep 2010

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

8 Sep 2010

Interventions targeting social cognition most effective in mitigating loneliness

Changing how a person perceives and thinks about others was the most effective intervention for loneliness, a sweeping analysis of previous research has determined. The findings may help physicians and psychologists develop better treatments for loneliness, a known risk factor for heart disease and other health problems.

8 Sep 2010

AHRQ releases free evidence-based guides for eight health conditions

HHS' Agency for Healthcare Research and Quality today released a series of free evidence-based guides designed to help Spanish speakers understand and compare the risks, benefits and side effects of treatments for eight health conditions.

7 Sep 2010

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

7 Sep 2010

Somaxon's Silenor now commercially available in U.S.

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that Silenor® (doxepin) now is commercially available by prescription in the United States. Somaxon has implemented a wholesale and retail stocking program to disseminate Silenor 3 mg and 6 mg dosepacks to pharmacies across the United States. Silenor is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

7 Sep 2010

Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study

A pilot study suggests the hallucinogen psilocybin may be feasible and safe to administer to patients with advanced-stage cancer and anxiety, with promising effects on mood, according to a report published online today that will appear in the January 2011 print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

7 Sep 2010

Study reveals high rate of parental depression in first year after child's birth

More than one-third of mothers and about one-fifth of fathers in the United Kingdom appear to experience an episode of depression between their child's birth and 12th year of age, with the highest rates in the first year after birth, according to a report posted online today that will appear in the November print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

7 Sep 2010

Psilocybin reduces anxiety, improves mood with advanced-stage cancer: Study

In the first human study of its kind to be published in more than 35 years, researchers found psilocybin, an hallucinogen which occurs naturally in "magic mushrooms," can safely improve the moods of patients with advanced-stage cancer and anxiety, according to an article published online today in the Archives of General Psychiatry.

7 Sep 2010

Depression News and Research

Latest Depression News and Research

Current economic crisis threatens to affect cancer incidence: Report

Accord reached on draft declaration for MDG summit

NAADAC and Hazelden partner to improve treatment for co-occurring disorders

Researchers present study results of psychosocial trauma experienced at 2006 Dawson College shooting

Purdue Pharma to present Butrans Transdermal System CIII clinical program data at PAINWeek 2010

Diplomat Specialty Pharmacy ranked #554 on Inc.'s Top 5000 list of fastest-growing private companies

Highlights of 23rd Congress of European College of Neuropsychopharmacology 2010

New research examines how music could benefit treatment of depression, management of physical pain

Nation's four leading ADHD organizations seek to end persistent myths about ADHD

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

Researchers to study suicide prevention program in high schools

ECNP honors Kaj Blennow with 2010 Neuropsychopharmacology Award

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

Interventions targeting social cognition most effective in mitigating loneliness

AHRQ releases free evidence-based guides for eight health conditions

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Somaxon's Silenor now commercially available in U.S.

Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study

Study reveals high rate of parental depression in first year after child's birth

Psilocybin reduces anxiety, improves mood with advanced-stage cancer: Study

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Depression News and Research

Latest Depression News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in